verified SJR 1,716 · Q1 • database Scopus / SJR & Web of Science indexed

Germany · Springer Science and Busines...

workspace_premium Q1 — Medicine (miscellaneous) lock_open Open Access

Cancer Immunology, Immunotherapy

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is k...

ISSN: 0340-7004

Publisher: Springer Science and Business Media Deutschland GmbH

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Visit publisher site menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,716 Q1

H-index 142

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,716

H-index

142

Docs (year)

257

Docs 3y

868

Total refs

11784

Cites 3y

4305

Citable 3y

860

Cites/Doc 2y

4.84

Ref/Doc

45.85

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

Two-dimensional gel analysis of polypeptides from normal, preneoplastic and neoplastic mouse mammary tissues

Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes

Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

Editorial statement from Graham Pawelec

Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients

Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study

SHOW MORE ARTICLES

Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells

Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapy

Cellular immunity for cancer chemoimmunotherapy?an overview

Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours

British Society for Immunology annual congress, Harrogate, UK, 2?5 December 2003

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism

A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays

A primer on cancer immunology and immunotherapy

FAQs

Cancer Immunology, Immunotherapy has an SJR of 1,716 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Cancer Immunology, Immunotherapy is 23%.

Cancer Immunology, Immunotherapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cancer Immunology, Immunotherapy?

What is the APC / publication cost?

What is the acceptance rate?